First-line lorlatinib or crizotinib in advanced <i>ALK</i>-positive lung cancer

In the international CROWN study, researchers evaluated the viability of lorlatinib vs. crizotinib as a first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer. The sample population for the Phase III trial included 296 treatment-naive patients, randomized into two cohorts.

In the international CROWN study, researchers evaluated the viability of lorlatinib vs. crizotinib as a first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer. The sample population for the Phase III trial included 296 treatment-naive patients, randomized into two cohorts. The results of a planned interim efficiency analysis revealed that 78% participants in the lorlatinib group remained alive and without disease progression at 12 months compared with 39% of participants in the crizotinib group. Objective response rates were 76% and 58%, respectively, and intracranial response rates were 82% and 23%, respectively. While these outcomes favor lorlatinib over crizotinib in this setting, researchers noted a higher incidence of grade 3 or 4 adverse events was associated with lorlatinib than with crizotinib.